Oligometastatic Non‐Small Cell Lung Cancer (NSCLC) presents a unique opportunity for
potential curative therapy. Improved cancer staging using PET/CT, MRI, and future cellular …

1.72–6.964, P= 0.001, respectively) and OS (HR 1.386; 95% CI: 1.107–1.735, P= 0.004; HR
3.894; 95% CI: 1.065–14.236, P= 0.040, respectively) on univariate analysis. On multivariate …

Oligometastatic disease (OMD) is no more and no less than what it say on the label. It is
cancer with few metastases, no more than can be counted on the fingers of one hand. A few …

Patients with oligometastatic disease (OMD) non-small cell lung cancer (NSCLC) are
considered as a subgroup of metastatic NSCLC that can obtain long-term survival or even …

Simple Summary Since the first introduction of the oligometastatic state with a low burden of
metastases in non-small cell lung cancer, accumulating evidence from retrospective and …

Simple Summary Metastatic non-small cell lung cancer (NSCLC) classically portends a poor
prognosis and worse overall survival. However, recent advances in modern systemic …

Metastatic lung cancer encompasses a heterogenous group of patients in terms of burdens
of disease, ranging from patients with extensive metastases to those with a limited number of …

To the Editor: We read with great interest the article by Lodeweges et al. published in the
Journal of Thoracic Oncology. 1 The article describes a study of registered patients with …

More than 50% of NSCLC patients present with metastatic disease at first diagnosis, with a
median survival of 8–11 months. However, selected patients with oligometastatic disease …

Objective In this review, the concept of (synchronous) oligometastatic disease in patients
with non-oncogene-driven non-small cell lung cancer (NSCLC) will be placed in the context …